USO 26014
A Phase 1b, Open-Label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-Resistant Prostate Cancer
Disease Types: Genitourinary Cancer Research
Eligibility Requirements:
• Histological, pathological and/or cytological confirmation of
adenocarcinoma of the prostate with evidence of progressive
disease
• Subjects must have prior orchiectomy and/or ongoing androgendeprivation therapy and a castrate level of serum testosterone
• Subjects must have progressed on at least one ARPI and received
exactly one prior taxane in the mCRPC setting
• Prior docetaxel in the mHSPC setting is allowed
• Subjects with CNS metastasis are excluded
• Subjects that received prior STEAP1-targeted therapy or CD3-
directed therapy are excluded
• Subjects with prior radionuclide therapy within 2 months of first dose
of study treatment are excluded
For more information on this trial CLICK HERE .
Available at: